Home/Pipeline/Filgotinib (JYSELECA)

Filgotinib (JYSELECA)

Ulcerative Colitis, Crohn's Disease

Approved (RA) / Phase 3ActiveN/A

Key Facts

Indication
Ulcerative Colitis, Crohn's Disease
Phase
Approved (RA) / Phase 3
Status
Active
Company

About Gilead

Gilead Sciences is a fully integrated biopharmaceutical giant with a mission to create a healthier world by advancing transformative therapies for serious diseases. It achieved historic success by pioneering curative treatments for hepatitis C and life-sustaining regimens for HIV, establishing a dominant virology franchise. The company's current strategy is to expand its leadership into oncology and inflammation through internal R&D and strategic acquisitions, while maintaining its commitment to health equity and global access.

View full company profile

Other Ulcerative Colitis, Crohn's Disease Drugs